I. INTRODUCTION — OVERVIEW
A APPLICATIONS OF BIOTECHNOLOGY
| FEATURE | DETAIL |
|---|---|
| Scope | Industrial scale production of biopharmaceuticals & biologicals using genetically modified microbes, fungi, plants & animals ⭐ |
| Applications include | Therapeutics, Diagnostics, Genetically modified crops (agriculture), Processed food, Bioremediation, Waste treatment, Energy production ⭐⭐ |
B THREE CRITICAL RESEARCH AREAS OF BIOTECHNOLOGY
| AREA | DETAIL |
|---|---|
| (i) | Providing the best catalyst — improved organism (usually a microbe) or pure enzyme ⭐ |
| (ii) | Creating optimal conditions through engineering for the catalyst to act ⭐ |
| (iii) | Downstream processing technologies to purify the protein/organic compound ⭐ |
C THREE OPTIONS FOR INCREASING FOOD PRODUCTION
| OPTION | DETAIL |
|---|---|
| (i) | Agro-chemical based agriculture ⭐ |
| (ii) | Organic agriculture ⭐ |
| (iii) | Genetically engineered crop-based agriculture ⭐⭐ |
| FEATURE | DETAIL |
|---|---|
| Green Revolution | Succeeded in tripling the food supply → but still NOT enough to feed growing human population ⭐⭐ |
| Problem with agrochemicals | Too expensive for developing world farmers; further yield increases not possible with conventional breeding ⭐ |
| Solution | Use of genetically modified crops ⭐⭐ |
II. TISSUE CULTURE
A OVERVIEW
| FEATURE | DETAIL |
|---|---|
| Discovery period | 1950s ⭐ |
| Explant | Any part of a plant taken out and grown in a test tube under sterile conditions in special nutrient media ⭐⭐⭐ |
| Key finding | Whole plant could be regenerated from an explant ⭐⭐ |
| Totipotency | The capacity to generate a whole plant from any cell/explant ⭐⭐⭐ |
Totipotency = capacity to generate whole plant from any cell/explant.
B NUTRIENT MEDIUM REQUIREMENTS
| COMPONENT | EXAMPLES |
|---|---|
| Carbon source | Sucrose ⭐⭐ |
| Inorganic salts | Various mineral salts ⭐ |
| Vitamins | Essential vitamins ⭐ |
| Amino acids | Required for growth ⭐ |
| Growth regulators | Auxins & Cytokinins ⭐⭐⭐ |
C MICROPROPAGATION
| FEATURE | DETAIL |
|---|---|
| Definition | Method of producing thousands of plants through tissue culture ⭐⭐⭐ |
| Genetic identity | Each plant is genetically identical to the original plant = Somaclones ⭐⭐⭐ |
| Commercial examples | Tomato, Banana, Apple etc. ⭐ |
Micropropagation → thousands of plants via tissue culture; genetically identical = somaclones.
D VIRUS-FREE PLANTS FROM MERISTEM CULTURE
| FEATURE | DETAIL |
|---|---|
| Key fact | Even if plant is infected with virus, the meristem (apical & axillary) is FREE of virus ⭐⭐⭐ |
| Method | Remove meristem → grow in vitro → obtain virus-free plants ⭐⭐⭐ |
| Examples | Meristem culture of Banana, Sugarcane, Potato ⭐ |
Meristem (apical & axillary) = free of virus; in vitro culture → virus-free plants.
E SOMATIC HYBRIDISATION
| FEATURE | DETAIL |
|---|---|
| Step 1 | Isolate single cells from plants → digest cell walls ⭐⭐ |
| Result | Naked protoplasts (surrounded by plasma membrane only) ⭐⭐⭐ |
| Step 2 | Protoplasts from two different varieties (each with desirable character) → fused ⭐⭐ |
| Product | Hybrid protoplasts → grown further to form new plant ⭐⭐ |
| Hybrids called | Somatic hybrids ⭐⭐⭐ |
| Process called | Somatic hybridisation ⭐⭐⭐ |
Somatic hybridisation = fusing protoplasts of two different plant varieties (after digesting cell walls); somatic hybrids.
Correct sequence of somatic hybridisation — Isolation of single cells from two different varieties of plants → Digestion of cell walls → Isolation of naked protoplasts → Fusion of protoplasts to get hybrid protoplast → Growing of hybrid protoplast to form a new plant.
Pomato — Classic Example ⭐⭐
| FEATURE | DETAIL |
|---|---|
| What | Protoplast of Tomato fused with protoplast of Potato ⭐⭐ |
| Result | Pomato — hybrid combining tomato & potato characteristics ⭐⭐ |
| Outcome | Unfortunately did NOT have all desired combination of characteristics for commercial utilisation ⭐ |
III. GENETICALLY MODIFIED ORGANISMS (GMOs)
A DEFINITION
| FEATURE | DETAIL |
|---|---|
| GMO = | Plants, Bacteria, Fungi & Animals whose genes have been altered by manipulation ⭐⭐⭐ |
B BENEFITS OF GENETIC MODIFICATION IN PLANTS
| BENEFIT | DETAIL |
|---|---|
| (i) | Made crops more tolerant to abiotic stresses — Cold, Drought, Salt, Heat ⭐⭐ |
| (ii) | Reduced reliance on chemical pesticides — pest-resistant crops ⭐⭐ |
| (iii) | Helped to reduce post-harvest losses ⭐⭐ |
| (iv) | Increased efficiency of mineral usage by plants (prevents early exhaustion of soil fertility) ⭐⭐ |
| (v) | Enhanced nutritional value of food — e.g., Golden Rice = Vitamin A enriched rice ⭐⭐⭐ |
GM plants — tolerant to abiotic stresses; pest-resistant; reduce post-harvest losses; increased mineral usage; enhanced nutrition (Golden Rice = Vitamin A).
Golden Rice = Vitamin A enriched rice (gene from Daffodil).
IV. BT COTTON & BT TOXIN
A OVERVIEW
| FEATURE | DETAIL |
|---|---|
| Bt toxin produced by | Bacterium Bacillus thuringiensis ⭐⭐⭐ |
| What was done | Bt toxin gene cloned from bacteria → expressed in plants → resistance to insects without insecticides = bio-pesticide ⭐⭐ |
| Examples of Bt crops | Bt cotton, Bt corn, Rice, Tomato, Potato, Soyabean ⭐ |
Bt toxin produced by Bacillus thuringiensis.
B INSECT GROUPS KILLED BY Bt STRAINS
| INSECT ORDER | EXAMPLES |
|---|---|
| Lepidopterans | Tobacco budworm, Armyworm ⭐⭐ |
| Coleopterans | Beetles ⭐⭐ |
| Dipterans | Flies, Mosquitoes ⭐⭐ |
C MECHANISM OF Bt TOXIN ACTION
| STAGE | DETAIL |
|---|---|
| 1. Production | B. thuringiensis forms PROTEIN CRYSTALS during a PARTICULAR PHASE of their growth ⭐⭐ |
| 2. State in bacteria | Crystals contain TOXIC INSECTICIDAL PROTEIN → exists as INACTIVE PROTOXIN ⭐⭐⭐ |
| 3. Ingestion | Insect INGESTS the inactive toxin ⭐ |
| 4. Activation | Converted into ACTIVE FORM of toxin due to ALKALINE pH of insect GUT ⭐⭐⭐ |
| 5. Binding | Activated toxin BINDS to surface of MIDGUT EPITHELIAL CELLS ⭐⭐⭐ |
| 6. Pore formation | Creates PORES ⭐⭐ |
| 7. Cell death | Causes CELL SWELLING & LYSIS ⭐⭐ |
| 8. Insect death | Eventually causes DEATH of insect ⭐ |
Bt toxin = inactive protoxin → activated by alkaline pH of insect gut → binds to midgut epithelial cells → creates pores → cell swelling & lysis → death.
The inactive form of Bt toxin is converted to the active form in the insect gut due to ALKALINE pH — not acidic pH, not by proteases, not by nucleases.
Why Toxin Does Not Kill the Bacillus? ⭐⭐⭐
| REASON | DETAIL |
|---|---|
| Answer | Bt toxin exists as inactive protoxin inside the bacterium ⭐⭐⭐ |
| Activation requires | Alkaline pH of insect gut → Bacillus does NOT have alkaline gut pH ⭐⭐ |
Crystals of Bt toxin do NOT kill the bacteria because toxin is inactive (not because bacteria are resistant, or toxin is in a special sac).
D CRY GENES — MASTER TABLE
| GENE | PROTEIN ENCODED | TARGET PEST | CROP |
|---|---|---|---|
| cryIAc | Cry IAc protein | Cotton bollworms ⭐⭐⭐ | Cotton |
| cryIIAb | Cry IIAb protein | Cotton bollworms ⭐⭐⭐ | Cotton |
| cryIAb | Cry IAb protein | Corn borer ⭐⭐⭐ | Corn |
| FEATURE | DETAIL |
|---|---|
| Toxin coded by gene named | cry ⭐⭐⭐ |
| Specificity | Most Bt toxins are insect-group specific ⭐⭐ |
| Choice depends on | The crop and the targeted pest ⭐ |
cry genes — cryIAc & cryIIAb = cotton bollworms; cryIAb = corn borer; toxin coded by gene cry; insect-group specific.
cryIAc & cryIIAb = cotton bollworms; cryIAb = corn borer — do not confuse!
cryIAc controls cotton bollworms and cryIAb controls corn borer, respectively. When the stem pairs cotton bollworms AND corn borer, respectively, the answer is cryIAc and cryIAb — cryIIAb is the second cotton bollworm gene and is the standing distractor.
V. PEST RESISTANT PLANTS — RNA INTERFERENCE (RNAi)
A THE PROBLEM
| FEATURE | DETAIL |
|---|---|
| Nematode | Meloidogyne incognitia ⭐⭐⭐ |
| Target plant | Infects roots of Tobacco plants ⭐⭐⭐ |
| Effect | Causes great reduction in yield ⭐ |
Meloidogyne incognitia infects roots of tobacco plants → reduces yield.
B STRATEGY — RNA INTERFERENCE (RNAi)
| FEATURE | DETAIL |
|---|---|
| RNAi = | RNA Interference ⭐⭐ |
| Occurs in | All eukaryotic organisms as a method of cellular defence ⭐⭐⭐ |
| Mechanism | Silencing of a specific mRNA due to a complementary dsRNA (double-stranded RNA) molecule ⭐⭐⭐ |
| How dsRNA works | Binds to mRNA → prevents translation of the mRNA = silencing ⭐⭐⭐ |
| Sources of complementary RNA | Infection by viruses with RNA genomes or mobile genetic elements (transposons) that replicate via RNA intermediate ⭐⭐ |
RNAi takes place in all eukaryotic organisms as method of cellular defence.
Silencing of specific mRNA due to complementary dsRNA → prevents translation.
RNAi involves dsRNA (double-stranded RNA), NOT single-stranded RNA.
Silencing of a specific mRNA via RNAi is possible because of complementary dsRNA — not complementary tRNA, non-complementary ssRNA or inhibitory ssRNA.
C APPLICATION TO TOBACCO-NEMATODE PROBLEM
| STEP | DETAIL |
|---|---|
| 1 | Using AGROBACTERIUM vectors ⭐⭐ |
| 2 | NEMATODE-SPECIFIC GENES introduced into HOST PLANT ⭐⭐ |
| 3 | DNA introduced such that it produced BOTH SENSE & ANTI-SENSE RNA in host cells ⭐⭐⭐ |
| 4 | These two RNAs are COMPLEMENTARY to each other ⭐ |
| 5 | Form DOUBLE-STRANDED RNA (dsRNA) ⭐⭐ |
| 6 | dsRNA initiates RNAi ⭐⭐ |
| 7 | SILENCED the specific mRNA of the NEMATODE ⭐⭐ |
| 8 | Parasite COULD NOT SURVIVE in transgenic host ⭐⭐ |
| 9 | Transgenic plant PROTECTED from the parasite ⭐ |
Nematode-specific gene → produces both sense & anti-sense RNA → dsRNA → RNAi → mRNA silencing → parasite cannot survive.
VI. BIOTECHNOLOGICAL APPLICATIONS IN MEDICINE
A RECOMBINANT THERAPEUTICS — OVERVIEW
| FEATURE | DETAIL |
|---|---|
| Impact | Immense impact in healthcare — mass production of safe & effective therapeutic drugs ⭐⭐ |
| Key advantage | Recombinant therapeutics do NOT induce unwanted immunological responses (unlike products from non-human sources) ⭐⭐⭐ |
| Globally | About 30 recombinant therapeutics approved for human use ⭐ |
| In India | 12 currently being marketed ⭐ |
B GENETICALLY ENGINEERED INSULIN
1. Historical Problem ⭐⭐
| FEATURE | DETAIL |
|---|---|
| Earlier source | Insulin extracted from pancreas of slaughtered cattle & pigs ⭐⭐ |
| Problem | Animal insulin caused some patients to develop allergy or other reactions to foreign protein ⭐⭐⭐ |
Insulin earlier from pancreas of slaughtered cattle & pigs → allergy/reactions to foreign protein.
2. Structure of Insulin ⭐⭐⭐
| FEATURE | DETAIL |
|---|---|
| Composition | Two short polypeptide chains ⭐⭐⭐ |
| Chains | Chain A & Chain B ⭐⭐⭐ |
| Linked by | Disulphide bridges ⭐⭐⭐ |
Insulin = two short polypeptide chains (A & B) linked by disulphide bridges.
3. Pro-hormone Concept ⭐⭐⭐
| FEATURE | DETAIL |
|---|---|
| In mammals | Insulin synthesised as a pro-hormone (like a pro-enzyme) ⭐⭐⭐ |
| Pro-hormone contains | Three peptides — A, B & C peptide ⭐⭐⭐ |
| C peptide | An extra stretch present in pro-hormone ⭐⭐ |
| During maturation | C peptide is REMOVED ⭐⭐⭐ |
| Mature insulin | Does NOT contain C peptide ⭐⭐⭐ |
| Main challenge | Getting insulin assembled into mature form using rDNA techniques ⭐⭐ |
Pro-hormone contains A, B & C peptide; C peptide removed during maturation; absent in mature insulin.
4. Eli Lilly rDNA Approach ⭐⭐⭐
| FEATURE | DETAIL |
|---|---|
| Year | 1983 ⭐⭐ |
| Company | Eli Lilly (American company) ⭐⭐⭐ |
| Method | Prepared two DNA sequences corresponding to A & B chains of human insulin ⭐⭐ |
| Introduced in | Plasmids of E. coli ⭐⭐⭐ |
| Production | Chains A & B produced separately ⭐⭐⭐ |
| Assembly | Extracted → combined by creating disulphide bonds → human insulin ⭐⭐⭐ |
Eli Lilly (1983) → A & B chains produced separately in E. coli → combined by disulphide bonds → human insulin.
The genetically engineered organism used by Eli Lilly to prepare human insulin was a BACTERIUM (Escherichia coli) — not a virus, phage or yeast.
C GENE THERAPY
1. Definition ⭐⭐⭐
| FEATURE | DETAIL |
|---|---|
| Definition | A collection of methods that allows correction of a gene defect that has been diagnosed in a child/embryo ⭐⭐⭐ |
| Method | Genes inserted into a person's cells and tissues to treat a disease ⭐⭐ |
| Involves | Delivery of a normal gene into individual/embryo → takes over function of & compensates for the non-functional gene ⭐⭐⭐ |
Gene therapy = correction of gene defect; delivery of normal gene to compensate for non-functional gene.
2. First Clinical Gene Therapy — ADA Deficiency ⭐⭐⭐
| FEATURE | DETAIL |
|---|---|
| Year | 1990 ⭐⭐⭐ |
| Patient | 4-year-old girl ⭐⭐⭐ |
| Disease | Adenosine Deaminase (ADA) deficiency ⭐⭐⭐ |
| ADA function | Crucial enzyme for immune system to function ⭐⭐ |
| Cause | Deletion of the gene for adenosine deaminase ⭐⭐ |
First gene therapy = 1990; 4-year-old girl; ADA deficiency.
3. Other Treatments for ADA Deficiency (Non-Gene Therapy) ⭐⭐
| TREATMENT | LIMITATION |
|---|---|
| Bone marrow transplantation | NOT completely curative ⭐⭐ |
| Enzyme replacement therapy | Functional ADA given by injection — NOT completely curative ⭐⭐ |
4. Gene Therapy Procedure for ADA ⭐⭐⭐
| STEP | DETAIL |
|---|---|
| 1 | LYMPHOCYTES from blood of patient ⭐ |
| 2 | Grown in CULTURE OUTSIDE THE BODY ⭐⭐ |
| 3 | Functional ADA cDNA introduced using a RETROVIRAL VECTOR ⭐⭐⭐ |
| 4 | Genetically engineered lymphocytes RETURNED TO THE PATIENT ⭐⭐ |
| FEATURE | DETAIL |
|---|---|
| Problem | These cells are NOT immortal ⭐⭐⭐ |
| Consequence | Patient requires periodic infusion of such genetically engineered lymphocytes ⭐⭐⭐ |
| Permanent cure | Gene isolated from marrow cells producing ADA → introduced into cells at early embryonic stages ⭐⭐⭐ |
ADA gene therapy — lymphocytes cultured outside body → functional ADA cDNA introduced (retroviral vector) → returned to patient; cells NOT immortal → periodic infusion needed.
Permanent cure = introduce ADA gene into cells at early embryonic stages.
Retroviral vector used to introduce DNA into human lymphocytes.
D MOLECULAR DIAGNOSIS
1. Overview ⭐⭐
| FEATURE | DETAIL |
|---|---|
| Purpose | Early diagnosis of diseases ⭐⭐ |
| Problem with conventional methods | Using serum & urine analysis → early detection is NOT possible ⭐⭐⭐ |
| Why? | Conventional methods detect pathogen only when symptoms appear → by then pathogen concentration is already very high ⭐ |
Conventional methods (serum & urine analysis) do NOT serve purpose of early diagnosis.
2. Techniques for Early Diagnosis ⭐⭐⭐
| TECHNIQUE | DETAIL |
|---|---|
| Recombinant DNA technology | Enables early diagnosis ⭐ |
| PCR (Polymerase Chain Reaction) | Detects very low concentration of bacteria/virus by amplification of nucleic acid ⭐⭐⭐ |
| ELISA (Enzyme Linked Immuno-Sorbent Assay) | Based on principle of antigen-antibody interaction ⭐⭐⭐ |
rDNA technology, PCR, ELISA — techniques for early diagnosis.
3. PCR Applications ⭐⭐⭐
| APPLICATION | DETAIL |
|---|---|
| Detects | Very low concentration of pathogen before symptoms appear ⭐⭐ |
| HIV detection | PCR routinely used to detect HIV in suspected AIDS patients ⭐⭐⭐ |
| Cancer detection | Used to detect mutations in genes in suspected cancer patients ⭐⭐ |
| Also identifies | Many other genetic disorders ⭐ |
PCR used for HIV detection in AIDS patients; detecting gene mutations in cancer patients.
PCR is used for amplification of nucleic acids, NOT for purification of isolated proteins.
4. Probe & Autoradiography ⭐⭐⭐
| FEATURE | DETAIL |
|---|---|
| Probe | A single-stranded DNA or RNA tagged with a radioactive molecule ⭐⭐⭐ |
| Method | Probe allowed to hybridise to its complementary DNA in a clone of cells ⭐⭐ |
| Detection by | Autoradiography ⭐⭐ |
| Mutated gene detection | Clone having mutated gene will NOT appear on photographic film ⭐⭐⭐ |
| Why? | Probe will NOT have complementarity with the mutated gene ⭐⭐⭐ |
Probe = single-stranded DNA/RNA tagged with radioactive molecule; hybridises to complementary DNA; autoradiography.
Mutated gene → no complementarity with probe → does NOT appear on film.
5. ELISA ⭐⭐
| FEATURE | DETAIL |
|---|---|
| Principle | Antigen-antibody interaction ⭐⭐⭐ |
| Detects infection by | Presence of antigens (proteins, glycoproteins) OR antibodies synthesised against pathogen ⭐⭐ |
ELISA based on antigen-antibody interaction.
VII. TRANSGENIC ANIMALS
A DEFINITION
| FEATURE | DETAIL |
|---|---|
| Definition | Animals that have had their DNA manipulated to possess & express an extra (foreign) gene ⭐⭐⭐ |
| Examples | Transgenic Rats, Rabbits, Pigs, Sheep, Cows, Fish ⭐ |
| Key statistic | Over 95% of all existing transgenic animals are Mice ⭐⭐⭐ |
95% of transgenic animals are mice.
B FIVE PURPOSES OF TRANSGENIC ANIMALS
| PURPOSE | DETAIL | EXAMPLES |
|---|---|---|
| (i) Normal Physiology & Development | Study how genes are regulated & affect normal body functions ⭐ | Study of insulin-like growth factor ⭐ |
| (ii) Study of Disease | Serve as models for human diseases ⭐⭐ | Cancer, Cystic fibrosis, Rheumatoid arthritis, Alzheimer's ⭐⭐⭐ |
| (iii) Biological Products | Produce useful biological products (medicines) ⭐⭐ | α-1-antitrypsin → treat Emphysema ⭐⭐⭐; Also PKU & Cystic fibrosis ⭐ |
| (iv) Vaccine Safety | Testing safety of vaccines before use on humans ⭐⭐ | Transgenic mice → test polio vaccine safety; could replace monkeys ⭐⭐ |
| (v) Chemical Safety Testing | Toxicity/safety testing ⭐ | Animals with genes making them more sensitive to toxic substances → results in less time ⭐ |
α-1-antitrypsin = human protein used to treat emphysema.
The human protein α-1-antitrypsin obtained from transgenic animals is used for the treatment of emphysema — not Alzheimer disease, rheumatoid arthritis or cystic fibrosis.
C ROSIE — FIRST TRANSGENIC COW
| FEATURE | DETAIL |
|---|---|
| Year | 1997 ⭐⭐⭐ |
| Name | Rosie ⭐⭐⭐ |
| Achievement | Produced human protein-enriched milk ⭐⭐⭐ |
| Quantity | 2.4 grams per litre ⭐⭐ |
| Protein | Milk contained human alpha-lactalbumin ⭐⭐⭐ |
| Significance | Nutritionally a more balanced product for human babies than natural cow-milk ⭐⭐ |
Rosie (1997) = first transgenic cow; produced human protein-enriched milk (2.4 g/L); contained human alpha-lactalbumin.
VIII. ETHICAL ISSUES
A NEED FOR REGULATION
| FEATURE | DETAIL |
|---|---|
| Concern | Genetic modification of organisms can have unpredictable results when introduced into ecosystem ⭐⭐ |
| Need | Ethical standards required to evaluate morality of activities that might help or harm living organisms ⭐ |
B GEAC
| FEATURE | DETAIL |
|---|---|
| Full form | Genetic Engineering Approval Committee ⭐⭐⭐ |
| Set up by | Indian Government ⭐⭐ |
| Function | Makes decisions regarding validity of GM research and safety of introducing GM organisms for public services ⭐⭐⭐ |
GEAC = Genetic Engineering Approval Committee; set up by Indian Government; decisions on GM research validity & safety.
C BIOPIRACY
| FEATURE | DETAIL |
|---|---|
| Definition | Use of bio-resources by multinational companies & other organisations WITHOUT proper authorisation from countries & people concerned AND WITHOUT compensatory payment ⭐⭐⭐ |
| Key context | Industrialised nations = rich financially but poor in biodiversity & traditional knowledge ⭐⭐ |
| Developing world | Rich in biodiversity and traditional knowledge related to bio-resources ⭐⭐ |
Biopiracy = use of bio-resources by MNCs without proper authorisation and without compensatory payment.
Biopiracy is by multinational companies/organisations, NOT by native people.
D RICE & BASMATI CONTROVERSY
| FEATURE | DETAIL |
|---|---|
| Estimated rice varieties in India | 200,000 varieties ⭐⭐ |
| Basmati documented varieties | 27 ⭐⭐ |
| Basmati characteristics | Unique aroma & flavour ⭐ |
| History | Grown in India for centuries; referenced in ancient texts, folklore, poetry ⭐ |
| Controversy | In 1997, an American company got patent rights on Basmati rice through US Patent & Trademark Office ⭐⭐ |
| Issue | 'New' variety was derived from Indian farmer's varieties (crossed with semi-dwarf varieties) → claimed as invention ⭐⭐ |
27 documented varieties of Basmati grown in India; American company patented Basmati (1997).
E OTHER PATENT ATTEMPTS
| FEATURE | DETAIL |
|---|---|
| Traditional herbal medicines targeted | Turmeric, Neem ⭐ |
| Protection | Indian Parliament cleared second amendment of Indian Patents Bill — includes patent terms, emergency provisions, R&D initiatives ⭐ |
IX. RAPID REVISION — KEY COMPARISON TABLES
TABLE 1: Tissue Culture Terms ⭐⭐⭐
| TERM | DEFINITION |
|---|---|
| Explant | Any part of a plant taken out & grown in vitro in nutrient media |
| Totipotency | Capacity to generate whole plant from any cell/explant |
| Micropropagation | Producing thousands of plants through tissue culture |
| Somaclones | Genetically identical plants produced by micropropagation |
| Protoplast | Plant cell after digesting cell wall (surrounded by plasma membrane only) |
| Somatic hybrids | Hybrids formed by fusing protoplasts of two different plant varieties |
| Pomato | Hybrid of Tomato + Potato protoplasts (commercially unsuccessful) |
TABLE 2: Bt Toxin — Complete Mechanism ⭐⭐⭐
| STAGE | DETAIL |
|---|---|
| 1. Production | B. thuringiensis forms protein crystals during a particular growth phase |
| 2. State in bacteria | Exists as inactive protoxin |
| 3–4. Ingestion & Activation | Insect ingests inactive toxin; alkaline pH of insect gut activates it |
| 5–8. Binding to death | Binds midgut epithelial cells → pores → swelling & lysis → insect dies |
TABLE 3: Cry Genes & Their Targets ⭐⭐⭐
| GENE | TARGET PEST | CROP |
|---|---|---|
| cryIAc | Cotton bollworms | Cotton |
| cryIIAb | Cotton bollworms | Cotton |
| cryIAb | Corn borer | Corn |
TABLE 4: Insulin — Key Facts ⭐⭐⭐
| FEATURE | DETAIL |
|---|---|
| Structure | 2 polypeptide chains (A & B) linked by disulphide bridges |
| Pro-hormone contains | A + B + C peptide |
| Mature insulin contains | A + B only (C peptide removed) |
| rDNA production (1983) | Eli Lilly; A & B chains produced separately in E. coli; combined by disulphide bonds |
TABLE 5: Gene Therapy — ADA Deficiency ⭐⭐⭐
| FEATURE | DETAIL |
|---|---|
| Year / Patient | 1990; 4-year-old girl |
| Cause | Deletion of ADA gene |
| Procedure | Lymphocytes cultured outside body → ADA cDNA via retroviral vector → returned to patient |
| Limitation | Cells NOT immortal → periodic infusion needed |
| Permanent cure | Introduce gene at early embryonic stage |
TABLE 6: Molecular Diagnosis Techniques ⭐⭐⭐
| TECHNIQUE | PRINCIPLE | APPLICATION |
|---|---|---|
| PCR | Amplification of nucleic acid | HIV detection; Cancer gene mutations |
| ELISA | Antigen-antibody interaction | Pathogen detection |
| Probe + Autoradiography | Radioactive-tagged ssDNA/RNA hybridises to complementary DNA | Mutated gene = no signal on film |
TABLE 7: Transgenic Animals — Five Purposes ⭐⭐⭐
| PURPOSE | EXAMPLE |
|---|---|
| Normal physiology & development | Insulin-like growth factor study |
| Study of disease | Cancer, Cystic fibrosis, Rheumatoid arthritis, Alzheimer's |
| Biological products | α-1-antitrypsin (emphysema) |
| Vaccine safety | Transgenic mice → polio vaccine safety testing |
| Chemical safety testing | Animals more sensitive to toxins → faster results |
TABLE 8: Key Years & Milestones ⭐⭐
| YEAR | EVENT |
|---|---|
| 1950s | Tissue culture developed |
| 1983 | Eli Lilly — genetically engineered insulin |
| 1990 | First clinical gene therapy — ADA deficiency |
| 1997 | First transgenic cow Rosie; American company patented Basmati |
TABLE 9: RNAi — Step by Step ⭐⭐⭐
| STEP | DETAIL |
|---|---|
| 1–2 | Nematode-specific genes introduced into host plant using Agrobacterium vectors |
| 3–4 | DNA produces both sense & anti-sense RNA → form dsRNA |
| 5–7 | dsRNA initiates RNAi → silences nematode mRNA → parasite cannot survive |
TABLE 10: GMO Benefits Summary ⭐⭐⭐
| BENEFIT | EXAMPLE |
|---|---|
| Abiotic stress tolerance | Cold, Drought, Salt, Heat resistant crops |
| Pest resistance | Bt cotton, Bt corn |
| Reduce post-harvest losses | GM crops with longer shelf life |
| Increased mineral usage efficiency | Prevents soil fertility exhaustion |
| Enhanced nutritional value | Golden Rice (Vitamin A) |
X. COMMON EXAM TRAPS — QUICK REFERENCE
CONSOLIDATED PYQ Q&A TABLE ⭐⭐⭐
| TRAP / QUESTION | CORRECT ANSWER |
|---|---|
| Totipotency = ? | Capacity to generate whole plant from any cell/explant ⭐⭐ |
| Somaclones = ? | Genetically identical plants from micropropagation ⭐ |
| Meristem infected with virus? | No — meristem (apical & axillary) is FREE of virus ⭐⭐⭐ |
| How to get virus-free plants? | Remove meristem → grow in vitro ⭐⭐ |
| Protoplast = ? | Plant cell with cell wall digested (plasma membrane only) ⭐⭐ |
| Somatic hybridisation sequence? | Isolate single cells → digest cell walls → isolate naked protoplasts → fuse protoplasts → grow into new plant ⭐⭐⭐ |
| Pomato = ? | Tomato + Potato protoplast fusion → commercially unsuccessful ⭐ |
| Golden Rice = ? | Vitamin A enriched rice (gene from Daffodil) ⭐⭐ |
| Bt toxin produced by? | Bacillus thuringiensis ⭐⭐ |
| Why Bt toxin doesn't kill the bacterium? | Exists as inactive protoxin inside bacteria ⭐⭐⭐ |
| What activates Bt protoxin in insect gut? | Alkaline pH ⭐⭐⭐ |
| Is Bt protoxin activated by acidic pH? | No ⭐⭐⭐ |
| Activated toxin binds to? | Surface of midgut epithelial cells ⭐⭐ |
| Cotton bollworms and corn borer, respectively? | cryIAc and cryIAb ⭐⭐⭐ |
| cryIAc & cryIIAb control? | Cotton bollworms ⭐⭐⭐ |
| cryIAb controls? | Corn borer ⭐⭐⭐ |
| Nematode in tobacco? | Meloidogyne incognitia ⭐⭐ |
| RNAi occurs in? | All eukaryotic organisms ⭐⭐ |
| mRNA silencing via RNAi due to? | Complementary dsRNA ⭐⭐⭐ |
| RNAi involves single or double-stranded RNA? | Double-stranded RNA (dsRNA) ⭐⭐⭐ |
| Earlier insulin source? | Pancreas of slaughtered cattle & pigs ⭐ |
| Insulin structure? | Two chains (A & B) linked by disulphide bridges ⭐⭐ |
| Mature insulin contains C peptide? | NO — C peptide removed during maturation ⭐⭐⭐ |
| Organism used by Eli Lilly for insulin? | Bacterium (E. coli) ⭐⭐⭐ |
| A & B chains produced together or separately? | Separately in E. coli → combined by disulphide bonds ⭐⭐⭐ |
| First clinical gene therapy — year / patient / disease? | 1990; 4-year-old girl; ADA deficiency ⭐⭐⭐ |
| ADA deficiency caused by? | Deletion of gene for ADA ⭐ |
| Vector used for ADA gene therapy? | Retroviral vector ⭐⭐ |
| Are engineered lymphocytes immortal? | NO — periodic infusion needed ⭐⭐⭐ |
| Permanent cure for ADA? | Introduce gene at early embryonic stages ⭐⭐ |
| Conventional diagnosis — early detection possible? | NO ⭐⭐ |
| PCR detects what in AIDS / cancer patients? | HIV / Gene mutations ⭐⭐ |
| PCR used for protein purification? | NO — only for nucleic acid amplification ⭐⭐ |
| Probe = ? | Single-stranded DNA/RNA tagged with radioactive molecule ⭐⭐ |
| Mutated gene — appears on film? | NO (no complementarity with probe) ⭐⭐⭐ |
| ELISA based on? | Antigen-antibody interaction ⭐⭐ |
| 95% of transgenic animals are? | Mice ⭐⭐⭐ |
| α-1-antitrypsin treats? | Emphysema ⭐⭐⭐ |
| First transgenic cow? | Rosie (1997) ⭐⭐⭐ |
| Rosie's milk protein / amount? | Human alpha-lactalbumin; 2.4 g/L ⭐⭐ |
| GEAC full form? | Genetic Engineering Approval Committee ⭐⭐⭐ |
| GEAC set up by? | Indian Government ⭐ |
| Biopiracy = ? | Use of bio-resources by MNCs without authorisation & without compensatory payment ⭐⭐⭐ |
| Biopiracy by native people? | NO — by multinational companies ⭐⭐ |
| Basmati varieties documented / patented? | 27; American company (1997) ⭐ |
| Carbon source / growth regulators in tissue culture? | Sucrose; Auxins & Cytokinins ⭐⭐ |